P2Y receptors in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is the most common cause of dementia, affecting more than 10% of people over the age of 65. Age is the greatest risk factor for AD, although a combination of genetic, lifestyle and environmental factors also contribute to disease development. Common features of AD are the formation of plaques composed of beta‐amyloid peptides (Aβ) and neuronal death in brain regions involved in learning and memory. Although Aβ is neurotoxic, the primary mechanisms by which Aβ affects AD development remain uncertain and controversial. Mouse models overexpressing amyloid precursor protein and Aβ have revealed that Aβ has potent effects on neuroinflammation and cerebral blood flow that contribute to AD progression. Therefore, it is important to consider how endogenous signalling in the brain responds to Aβ and contributes to AD pathology. In recent years, Aβ has been shown to affect ATP release from brain and blood cells and alter the expression of G protein‐coupled P2Y receptors that respond to ATP and other nucleotides. Accumulating evidence reveals a prominent role for P2Y receptors in AD pathology, including Aβ production and elimination, neuroinflammation, neuronal function and cerebral blood flow.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Neurovascular regulation in the normal brain and in Alzheimer's disease
Iadecola, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1387 · Cited by 2,213
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061 · cited 2×
“…α-secretases (i.e., ADAM9/10/17) and β-secretase (i.e., BACE1) in APP processing has been documented (Skovronsky et al., 2000; Deuss et al., 2008; O’Brien and Wong, 2011; Lichtenthaler, 2012) and production of neurotoxic Aβ is reduced by promoting α-secretase activity (Caccamo et al., 2006;…”
BackgroundNucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., Park, D., Woodson, R. I., Ostankovich, M., Sharma, P., et al. (2009) · Nature · doi:10.1038/nature08296 · Cited by 1,654 · cited 1×
“In monocytes and macrophages, the P2Y2R is a critical sensor of nucleotides released by apoptotic cells, whose phagocytic clearance function is promoted (Elliott et al., 2009).”
BackgroundThe P2Y12 receptor regulates microglial activation by extracellular nucleotides
Haynes, S. E., Hollopeter, G., Yang, G., Kurpius, D., Dailey, M. E., Gan, W.-B., & Julius, D. (2006) · Nature Neuroscience · doi:10.1038/nn1805 · Cited by 1,542 · cited 7×
“Interestingly, it was found that ‘resting’ (albeit quite dynamic) microglia express more P2Y12R than activated microglia (Haynes et al., 2006), whereas the immunoreactivity of P2Y12R was not observed in macrophages in spleen or abdominal cavity (Sasaki et al.”
BackgroundResultInfluentialNeuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 2×
“The crucial role of microglia in controlling Aβ levels has been demonstrated in AD mouse models and AD patients where Aβ immunisation has been shown to decrease plaque load and increase microglial cell accumulation (Schenk et al., 1999; Nicoll et al., 2003; Boche et al., 2010).”
BackgroundKawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053 · cited 1×
“Published by John Wiley & Sons Ltd 9 L. Erb and others (Hsiao et al., 1996; Kawarabayashi et al., 2001; Westerman et al., 2002).”
MethodRapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease
Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C., Garcia-Alloza, M., de Calignon, A., Rozkalne, A., Koenigsknecht-Talboo, J., Holtzman, D. M., Bacskai, B. J., & Hyman, B. T. (2008) · Nature · doi:10.1038/nature06616 · Cited by 987 · cited 1×
“…thought to play a neuroprotective role in AD by migrating towards Aβ plaques (Perlmutter et al., 1990; Frautschy et al., 1998; Bolmont et al., 2008; Meyer-Luehmann et al., 2008; Zheng et al., 2010) and clearing neurotoxic Aβ by endocytosis (Shie et al., 2005; Bolmont et al., 2008; Kim et al.,…”
BackgroundInflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · cited 4×
“While clinical trials of anti-inflammatory drugs are still inconclusive for AD treatment (Wyss-Coray and Rogers, 2012), modulation of inflammation has been effective in animal models of AD (McGeer et al.”
BackgroundInfluential
Cited by
Purinergic Signalling: Therapeutic Developments
Burnstock, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00661 · Cited by 398
Pun, F. W., Liu, B. H. M., Long, X., Leung, H. W., Leung, G. H. D., Mewborne, Q. T., Gao, J., Shneyderman, A., Ozerov, I. V., Wang, J., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.914017 · Cited by 115
“While it may execute its neuroprotective function by inhibiting the expression of MMP9 in AD (Erb et al., 2015), increased P2RY14 expression was observed in rat primary LPS-mediated microglial activation (Bianco et al., 2005), correlating with neuroinflammation.”
BackgroundNeutrophil/Lymphocyte, Platelet/Lymphocyte, and Monocyte/Lymphocyte Ratios in Mood Disorders
Marazziti, D., Torrigiani, S., Carbone, M. G., Mucci, F., Flamini, W., Ivaldi, T., & Dell'Osso, L. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867328666210922160116 · Cited by 61
Ernest James Phillips, T., & Maguire, E. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.652593 · Cited by 33
Metadata
- Authors
- Erb, L., Cao, C., Ajit, D., & Weisman, G. A.
- Venue
- Biology of the Cell
- Publisher
- Wiley
- Published
- 2014-10-13
- Volume
- 107
- Issue
- 1
- Pages
- 1-21
- ISSN
- 0248-4900 (ISSN-L)
- 1768-322X
- OpenAlex
- W1605778153
- Cited by
- 43
- References
- 45
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.